On 13 October 2026 the FDA recorded a supplement to an abbreviated new drug application for a generic buprenorphine product. The public record names only the application and manufacturer; it does not describe the content of the supplement, which for generic products commonly covers manufacturing, labelling or packaging changes.
Nothing in the notice indicates a new safety concern or a change to buprenorphine's indications. It does not alter perioperative management of patients taking buprenorphine.
- This is an administrative supplement to a generic application, not a safety communication.
- No change to buprenorphine's indications or warnings is described.
- Perioperative plans for patients on buprenorphine are unaffected by this notice.
- Formulation and route differ across buprenorphine products; confirm which one a patient takes.
Why it matters
It keeps the record of buprenorphine supply changes visible for teams that manage these patients perioperatively.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free